SPECIAL REPORT: LDA MEETS WITH FDA ON LYMERIX On January 22, 2002 in Bethesda, MD., the LDA was able to get a private meeting with the FDA on the vaccine issue, despite reluctance by the FDA to grant the meeting. Congressman Chris Smith helped facilitate the setup of this meeting. Patricia Smith, President, Lyme […]
This section contains information from the three branches of the federal government: Executive, Legislative, and Judicial. The Lyme Disease Association, Inc. (LDA) has been instrumental for decades in playing a leadership roll in shaping government actions and public policy concerning Lyme and tick-borne diseases.
I am here today because we do favor a safe and effective vaccine, but we are unsure whether an OSP A based vaccine can meet those criteria. Since the inception of OSP A vaccine trials, we heard from individuals experiencing difficulties after immunization. The information was startling, not only because of the problems described, but […]
Assays for Antibodies to Borrelia burgdorferi; Limitations, Use, and Interpretation for Supporting a Clinical Diagnosis of Lyme Disease July 7, 1997 Purpose FDA is advising you about the potential for misdiagnosis of Lyme disease. The results of commonly marketed assays for detecting antibody to Borrelia burgdorferi (anti-Bb), the organism that causes Lyme disease, may be […]
THE LDANJ VISITS THE US ARMY CENTERS FOR HEALTH PROMOTION & PREVENTION, CHPPM by: Pat Smith, with input from Corey Lakin and USACHPPM In May 1999, Association Vice President Corey Lakin and I visited the US Army Centers for Health Promotion and Prevention, USACHPPM, at Aberdeen Proving Grounds, Maryland. USACHPPM is the preventive medicine arm […]